Covalon Technologies has signed an agreement with a China-based partner for the distribution of its ColActive Plus Ag.

ColActive Plus Ag is a collagen matrix wound dressing used to treat chronic wounds and diabetic ulcers.

Under the agreement, Covalon will provide $12m over the term, with a minimum commitment of $500,000 in the first 12 months following regulatory approval in China.

Covalon CEO Brian Pedlar said the company expects to expand its relationship through the distribution of additional medical products.

Covalon develops new healthcare technologies which are used to detect, prevent and manage medical conditions including wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility.